---
title: Tirzepatide for Obesity Treatment and Diabetes Prevention
date: '2024-11-13'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39536238/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20241114180133&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Three years of treatment with tirzepatide in persons with
  obesity and prediabetes resulted in substantial and sustained weight reduction and
  a markedly lower risk of progression to type 2 diabetes than that with placebo.
  (Funded by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Three years of treatment with tirzepatide in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than that with placebo. (Funded by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, ...